Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial

Zealand Pharma lost about 20% of its market value after a late-stage trial showed many patients discontinued the weight-loss drug because of tolerability issues. The result raises concerns about the drug's commercial prospects and the company's near-term valuation. The move is likely to pressure the stock materially, though the impact is company-specific rather than sector-wide.